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1. Introduction
Glioblastoma Multiforme is the most malignant of gliomas. These malignancies that arise from
glial cells remain one of the pre-eminent and confounding therapeutic challenges in oncology
and medicine at-large. Though uncommon, it continues to be responsible for disproportionate
rates of morbidity and mortality the world over, as qualified by a median survival of only
about 15 months despite optimal treatment [1, 2]. This is in large part due to its heterogeneous
biology, exceedingly complex molecular pathogenesis, and the tumor's predilection for growth
in the CNS. Ongoing research, particularly in the last decade, has provided the scientific and
medical worlds with ever deeper insight into, and further elucidation of, the biology and
molecular pathogenesis of Glioblastoma Multiforme (GBM). This in turn has led to compelling
novel treatment modalities that range from rudimentarily conceptual to, excitingly, on the very
cusp of implementation. This chapter aims to provide the reader with a comprehensive survey
of Glioblastoma Multiforme contextualized within the broader realm of malignant gliomas.
GBM is the most common malignant primary brain cancer in adults, accounting for roughly
3 new cases per 100,000 people [3]. Underscoring its importance as a therapeutic target, GBM
accounts for nearly 16% of all brain tumors and, furthermore, nearly 46% of malignant gliomas
[3]. The average age at diagnosis of GBM is 64 years of age, and, for reasons yet unclear, it has
demonstrated a clear male predilection, being about 1.6 times more common in males than
females [3].
Running in tandem with the quest for more effective therapies for GBM has been a long and
intensive search for clear risk factors positively associated with the development of GBM. This
search, however, has been fraught with many dead ends. Indeed, no clear inciting cause has
been identified for the vast majority of cases of GBM and the only bona-fide established risk
factor is exposure to ionizing radiation. The cause-effect relationship between ionizing
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radiation and the development of GBM was established with studies that demonstrated that
children treated with radiotherapy for malignancies like leukemia have a markedly increased
risk for developing GBM [4]. Family history of cancer of any type also has a suggested
association, being found in the family members of roughly 19% of patients diagnosed with
GBM in one small study [5]. In a small minority, approximately 5%, of diagnosed primary
brain tumors, there is the presence of genetically inherited syndromes (e.g. Neurofibromatosis
Types I and II, Li-Fraumeni Syndrome, von Hippel-Lindau Syndrome, Turcot Syndrome,
Tuberous Sclerosis), which suggests a putative genetic relationship [6]. As with other malig‐
nancies, it has also been suggested that viral infections, specifically by SV40, HHV-6, and CMV,
may be associated with the development of GBM by tumorigenesis through integration of viral
genetic material into normal DNA [7-10]. Another putative association that has garnered much
in the way of publicity is the relationship between cell phone use and development of primary
brain tumors. This is a weakly-supported association based on the aggregate epidemiological
data on hand that deserves further study and follow-up in the years to come as cell phone use
becomes more ubiquitous the world over [11,12].
2. Histopathology
GBM is, in a manner of speaking, the pathological culmination of and histological end point
on the broader continuum of gliomas/astrocytomas. The word Glioma literally translates in
Greek into the English equivalent of "glue" [13]. This connotates the functional conception of
the cells that beget gliomas, i.e. gliomas arise from those cells in the CNS that form the support
framework for neurons. It merits a side note here that though this has been the traditional
conception of glial cells, new studies have shown them to possess a more autonomous role
than previously supposed [15]. The WHO has classified gliomas/astrocytomas into 4 grades
that, successively, convey graver prognostic significance (See Table 1); this is the 4th iteration
of this classification system published in 2007 and originally conceived in 1979 [15]. This
method of classification, based on histopathological features, is one that has built a certain
assumed relevance for clinical decision making. The neuro-oncologist uses it as a template to
guide whether a patient may qualify for a conservative strategy of watchful waiting, as with
Grades I and sometimes with Grade II, or aggressive radiotherapy with chemotherapy, as with
Grades III and IV. Indeed, only Grades III (Anaplastic astrocytoma/oligodendroglioma) and
IV (GBM) are considered malignant gliomas. There are discrete histological features that
qualify Grade III and IV astrocytomas as malignant. Grade III gliomas when compared to lower
grades, is distinguished by a significant increase in cellularity, mitotic activity, and nuclear
atypia [16] (See Figure 3). Grade IV gliomas, in addition to these telltale harbingers of malignant
transformation, is embodied, uniquely, by areas of microvascular proliferation and/or
neoplastic tissue necrosis [16] (See Figure 4). Indeed, it is worthy of emphatic mention that one
of the overarching and typifying characteristics of malignant gliomas is their histological
heterogeneity, i.e. consisting of both neoplastic and stromal tissue [16]
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Localized Astrocytoma
WHO Grade I
Pilocytic Astrocytoma
Pleomorphic Xanthoastrocytoma
Subependymal Giant Cell Astrocytoma
Diffuse Astrocytomas/Oligodendrogliomas
WHO Grade II (Astrocytoma)
Fibrillary
Protoplasmic
Gemistocytic
WHO Grade II (Oligodendroglioma_
WHO Grade III (Anaplastic Astrocytoma)
WHO Grade III (Anaplastic Oligodendroglioma)
WHO Grade IV (Glioblastoma Multiforme)
Giant Cell Glioblastoma
Gliosarcoma
Table 1. WHO Classification of Gliomas
Figure 1. Gross Appearance of GBM
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Figure 2. Gross Appearance of GBM
Figure 3. Histological Appearance of Grade III Anaplastic Oligodendroglioma. [16]
Figure 4. Histological Appearance of GBM. First Panel shows Pseudopalisading Nuclei at area of asterisk; second panel
shows mitotic figures at arrows and endothelial proliferation at asterisk. [16]
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The pathology of GBM, quite simply, is summated by foci of necrotic tissue surrounded by
anaplastic cells and microvascular hyperplasia. The anaplastic cells surrounding the foci of
necrosis are unique for malignant gliomas and are known as “pseudopalisading cells” due to
their configuration around the necrotic foci (Refer to asterisk in Figure 4, which shows a
necrotic center surrounded by pseudopalisading cells). It is interesting to note that the
pseudopalisades, hyperplastic vasculature and necrotic centers are all inextricably linked to
one another. The pseudopalisading cells are found to be severely hypoxic which causes over-
expression of hypoxia-inducible factor (HIF-1) and secretion of pro-angiogenic factors VEGF
and IL-8. It is thought that the telltale hypoxia and necrosis that distinguish malignant gliomas
arise as a result of vascular occlusion and intravascular thrombosis that are inevitable conse‐
quences of tumor outgrowing blood supply. By this model, then, the pseudopalisading nuclei
are seen as waves allowing for tumor cells to extend outwards from necrotic foci into normal
surrounding parenchyma [33]. Another tumor type of neuroepithelial tissue with malignant
capacity is oligodendroglioma. This type of tumor usually presents in younger patients within
the white matter of the frontal and temporal lobes. Histologically, oligodendrogliomas are
characterized by round nuclei and perinuclear halos dispersed in a monotonous pattern. The
perinuclear halos are a preparation artifact that is characteristic of oligodendrogliomas and
are frequently described as having a “fried-egg appearance”. This type of tumor can be
classified as WHO grade II or III (diffuse oligodendroglioma and anaplastic oligodendroglio‐
ma respectively) and the presence of a high mitotic rate (most 5-10%), vascular endothelial
hyperplasia and nuclear pleomorphism categorizes the tumor as Grade III anaplastic oligo‐
dendroglioma.
When one considers the origin of malignant gliomas, i.e. the inciting events that herald
transformation of normal glial tissue/parenchyma into malignant tissue, they conform to the
general oncological orthodoxy. That is, they are basically the end-result of stepwise mutations
in genes responsible for essential biological processes, most notably cell growth, proliferation
and controlled cell death. Oncogenesis of GBM is essentially representative of that basic canon
in oncology--activation of oncogenes and silencing of tumor suppressor genes. In other words,
stepwise acquisition of new biological properties/characteristics by oncogenesis confers
phenotypic characteristics that allow the malignant cells to outcompete their wild-type
counterparts in their micro-mileu.
3. Primary vs. secondary GBM
Upon diagnosis, GBM is customarily delineated into one of two broad categories--Primary
GBM, which arises de novo in brain tissue, or Secondary, which develops from lower grade
astrocytomas (Refer to Table 2 for salient respective features and differences). In addition to
the fundamental etiological difference, primary GBM possesses categorically different genetic
and epigenetic differences from Secondary GBM. (Epigenetics refers to those meiotically or
mitotically heritable traits resulting in phenotypic/gene expression patterns not related to
changes in the underlying actual DNA code.) The vast majority of cases are GBM are primary,
i.e. de novo, and comprise upwards of 90% of diagnosed cases. Epidemiologically, Primary
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GBMs are almost always found in the elderly population with a mean age of diagnosis of 62
years and is characterized by a rapidly inexorable course till death [27]. The genetic/epigenetic
features that beget the malignant transformation in primary GBM and encompass its difference
from secondary GBM include: mutations in and amplification of EGFR, loss of heterozygosity
of Chromosome 10q, deletion of the phosphatase and tensin homologue (PTEN) on Chromo‐
some 10, and p16 deletion [16,23]. Secondary GBM, on the other hand, predominantly affects
younger patients with a mean age at diagnosis of 45 years, and is characterized by a much
slower, more smoldering course than Primary GBM [23]. Secondary GBM evolves from Grade
II (Low Grade Well-Differentiated) and Grade III (Anaplastic) astrocytomas, has a predilection
for the frontal lobes, and develops from its precursors over the course of years. An epidemio‐
logical study from 2005 showed that the time of progression from low-grade astrocytoma to
GBM was approximately 5.3 years whereas the time of progression from anaplastic astrocy‐
toma to GBM was approximately 1.4 years [28]. This stands in stark contrast to the rapidity of
Primary GBM progression, with roughly two-thirds of patients having a clinical history from
time of diagnosis to death of less than 3 months [27]. As stated, secondary glioblastoma has a
genetic/epigenetic footprint that differs from Primary GBM, the exception being the common‐
ality of loss of heterozygosity of Chromosome 10q. The differences in this epigenetic footprint
include: mutations in p53, over expression of Platelet-Derived Growth Factor Receptor
(PDGFR), aberrancies in p16/Retinoblastoma pathways, and global differences in transcription
patterns and DNA copy numbers [16]. It is worthy of emphatic mention here that primary and
secondary GBM, though developing through distinct genetic and molecular pathways, are
grossly and histologically indistinguishable from one another.
Primary GBM Secondary GBM
Mean Age at Diagnosis ~ 62 years of age ~45 years of age
Percentage of Cases > 90% < 10%
Clinical Course Rapid Smoldering
Genetic Hallmarks EGFR, etc. PDGFR, etc.
Table 2. Primary vs. Secondary GBM
4. Clinical characteristics
The clinical presentation of GBM is, as intuited, dependent in large part on the location of the
tumor. Continuing to bode ill for both treatment and prognosis is the sobering fact that
malignant gliomas, and GBM in particular, grow insidiously and largely asymptomatically
until they are big enough to elicit symptoms by sheer mass effect. By that time, tellingly, the
options for surgical resection are relatively limited given extension into vital CNS parenchyma.
Common presenting symptoms include recalcitrant headaches, unprovoked new-onset
seizures, unprecedented memory loss, unaccountable changes in personality or consciousness,
cognitive/language impairments, and other miscellaneous symptoms, i.e. nausea/vomiting.
Tumors of the Central Nervous System – Primary and Secondary8
Though there are no pathognomonic symptoms that may help the clinician to reliably
distinguish between the two WHO Grades of malignant gliomas, there have been cohort
studies done that have shown some nuances in symptomatology between Anaplastic
Astrocytoma and Glioblastoma Multiforme (See Table 3). Prognostic factors boding favorably
for patients diagnosed with malignant gliomas include a lower tumor grade, resection of tumor
mass, younger age (less than 50 years) at time of diagnosis, higher performance status (e.g.
ECOG) score and intact neurological function [35].
Symptom Grade III, % Grade IV, %
Headache 53 57
Seizure 56 23
Memory Loss 26 39
Motor Weakness 25 36
Visual Symptoms 23 21
Language Deficits 22 36
Cognitive Changes 22 39
Personality Changes 11 27
Change in Consciousness 11 18
Nausea and Vomiting 8 15
Sensory Deficit 5 12
Papilledema 5 5
Table 3. Initial Symptoms in 565 Patients with Grade III or Grade IV Malignant Glioma (Data from Glioma Outcomes
Project [29])
5. Diagnosis
The diagnostic modalities for suspected GBM in the appropriate clinical setting are, broadly,
twofold: imaging and biopsy. The cornerstone of imaging is MRI with and without Gadolinium
contrast enhancement. Prior to administration of contrast, malignant gliomas are hypo-intense
on T1-weighted images (See Figure 5). Upon administration of Gadolinium, it is found that
tumor enhances heterogeneously; this allows it to be distinguished from surrounding edema
that remains hypo-intense on T-1 weighted images (See Figure 5). Another ancillary MRI sub-
modality is FLAIR (Fluid Attenuated Inverse Reconstruction) MRI (See Figure 5) [30]. The
utility of FLAIR MRI is that, as an inversion recovery MRI technique, it can essentially nullify
or subtract the effects of fluid, thereby suppressing CSF in brain imaging. This can be especially
useful in planning radiation therapy (to be discussed in more detail below) when it is of vital
importance to delineate malignancy from native vital brain parenchyma [31].
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Figure 5. (A) T1 pre-contrast images exhibit a hypointense lesion in the left frontal lobe region (arrow). (B) Axial T1
post-contrast images, after injection of 20 cc of intravenous MultiHance®, demonstrate a focus of enhancement in left
frontal lobe. (C) Axial T2 FLAIR images show increase in FLAIR signal in the left frontal lobe, which demonstrates en‐
hancement. (D) T2 FSE images also demonstrate increase in signal in the region of the left frontal lobe.[30]
The gold standard for diagnosis, of course, remains procurement of tissue for histological
confirmation that can either be accomplished either diagnostically through stereotactic biopsy
or, more commonly, diagnostically and therapeutically with tissue samples obtained during
craniotomy for the purposes of tumor resection or debulking.
6. Role of surgical resection
The standard treatment for newly-diagnosed GBM has remained relatively staid as evinced
by the relatively abysmal prognosis over the aggregate of decades. However, caveat emptor
must once again be invoked as there is a sea change in elucidation of the molecular features
of GBM that promises much in the way of therapeutic potential on the horizon. This will be
discussed in detail in content to follow.
The first modality in treatment is maximally safe surgical resection. This, it needs bearing in
mind, is not curative. At the time of diagnosis, newly-found GBM has invariably infiltrated
extensively into normal brain parenchyma. GBM is almost always diagnosed after it has grown
large enough to elicit symptoms due to mass effect and parenchymal disruption. However,
the benefits of maximally-safe surgical resection of tumor are manifold: sampling of tissue for
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pathological diagnosis, palliation of mass effect, and some indication of improvement in
survival [16]. Though rote surgical resection has remained somewhat limited due to the
intricate insinuation of the tumor into brain tissue, new surgical technologies have allowed for
more elegant and discriminating extrication of malignant tissue. One example is neuroendo‐
scopy, use of an endoscope deployed through the ventricles for a minimally-invasive approach
to allow for biopsy, resection and alleviation of lesions causing obstructive hydrocephalus [13].
Another surgical technology is fluorescence-guided resection. This involves the administra‐
tion of a non-fluorescent prodrug 5-aminolevulinic acid (ALA) that, when taken up by tumor
tissue, is converted to fluorescent metabolite protoporyphyrin IX (PpIX) and accumulates to
a marked degree in Grade III and IV gliomas. The neurosurgeon intra-operatively deploys
“blue light” which allows tumor tissue to be visualized as “red” due to the fluorescent
biomarker. This, in turn, has been shown to allow for more optimal and extensive tumor
resection [13] (See Figure 6).
Figure 6. Flourescence/ALA-Guided Surgical Resection of GBM [13]
An important concept to invoke here in the discussion of surgical treatment is Extent Of
Resection (EOR), i.e. the extent of tumor tissue that can be safely resected. There is, as would
be intuited, a likely positive association between (EOR) and patient survival/patient outcome.
Data from the ALA-glioma Study Group out of Germany provided the highest level of
evidence--2b--for a positive association between patient outcome, i.e. progression free
High Grade Glioma — Standard Approach, Obstacles and Future Directions
http://dx.doi.org/10.5772/58548
11
survival, and EOR [34]. There are, however, some retrospective studies (volumetric and non-
volumetric) that have shown no survival benefit with increased EOR. However, the aggregate
of evidence does support the thesis that patients with high-grade gliomas do show survival
benefit with increased EOR.
7. Standard adjuvant therapy
After maximally-safe surgical resection, the standard of care for GBM is a 6 week course of
External Beam Focused Radiation Therapy with concurrent chemotherapy followed by 6
months of adjuvant chemotherapy.
With the support of Level IA evidence, fractionated focal radiotherapy (60 Gy, 30-33 fractions
of 1.8-2 Gy) is the established radiation regimen after resection or biopsy of malignant gliomas
[37]. The fundamental nature of the ionizing radiation utilized has, needless to say, not
changed; however, leaps and bounds have been made in efforts to focus the beam, tailor it to
the highly-serrated and convoluted contours of tumor, and limit the dose to nearby critical
structures/tissue by the use of intensity-attenuated and image-guided technologies, all with
positive effect.
The single first-line chemotherapeutic agent for GBM is temozolomide, an oral alkylating agent
that exerts its anti-tumorigenic effect by methylating/alkylating DNA at the N-7/O-6 positions
of guanine residues, thereby causing irreparable damage to (tumor) DNA and instigating the
process of tumor cell death. The benefits of the addition of concurrent with adjuvant chemo‐
therapy to the foundation of radiation therapy were demonstrated by a seminal landmark
study by Stupp et al that showed a 14.6 to 12.1 month median overall survival benefit and
showed a sustained survival advantage of 9.8% vs 1.9% at 5 year analysis (Figure 7) [35].
High-dose corticosteroids have a role to play in reduction of tumor-associated edema and
associated symptoms but are not indicated for long periods of time [37]. There is an established
role for anti-seizure therapy in patients who present with seizures, but the role for seizure
prophylaxis after surgery is only indicated in symptomatic patients. It ought to be kept in mind
Figure 7. EORTC/NCIC Trial 5-Yr Follow-up [35]
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that many anti-epileptics, particularly of the first generation (e.g. phenytoin, carbamazepine),
may decrease the serum concentration of certain chemotherapy agents by dint of inducing
increased hepatic metabolism [37].
As evinced by the yet-sobering statistics on overall GBM survival/patient outcome, there are
many-a-challenge and obstacle that remain in treatment, especially regarding the development
of resistance to both radiation therapy and, more so, to temozolomide chemotherapy.
8. Signaling pathways in high grade glioma
To understand the fundamentals of GBM oncogenesis, it is essential to understand that that
there are certain cellular signal transduction pathways responsible for cell proliferation that
are normally highly regulated. However, in malignant gliomas, these pathways aberrantly
lose regulatory control and end up constitutively activated to disastrous consequence. This
occurs mainly through anomalies in the receptors that initiate the signal transduction cascades
for growth factors. In one common mechanism, epigenetic mutations result in overexpression
or amplification of the genes that encode growth factor receptors. Increased expression of these
growth factor receptors results in increased activation of signal transduction cascades. This
ultimately yields exponentially increased expression of growth factors which begets malignant
cellular proliferation [16].
Some of the best-characterized growth factor mutations in GBM oncogenesis are, as previously
introduced, EGFR in primary GBM and PDGFR in secondary GBM. In upwards of 40% of cases
of primary GBM, EGFR is amplified to significant pathologic effect (27). Most cases have a
genetic lesion of EGFR from deletion of exons 2-7 that results in the anomalous gene EGFR‐
vIII. The normal gene product of the wild-type EGFR gene is the EGFR receptor. This receptor,
by default, is phosphorylated at the intracellular domain which sets in motion a cascade of
signal transduction events that culminates in cell proliferation and survival. In normal cells,
the EGFR receptor is regulated by binding of extracellular ligands to the extracellular domain
which acts to antagonize phosphorylation at the intracellular domain and thereby down-
regulate the mitogenic function of the growth factor cascade. The mutant gene EGFRvIII
generates the aberrant gene product EGFRvIII that is constitutively phosphorylated/activated
due to lacking a down-regulating extracellular ligand-binding domain that would otherwise
have been coded by the missing exons 2-7 [16].
There is an ever-burgeoning body of information with the molecular features of malignant
gliomas that casts the WHO system in a stark light for the limitations it makes apparent. This
molecular information has allowed for determination of discrete subtypes of gliomas within
each WHO grade that, through the rigors of clinical trials, have borne out true clinical utility
for diagnosis, prognostication and treatment [13]. Within one grade, molecular signatures have
identified subtypes that respectively take demonstrably different clinical courses and have
discrete treatment responses. Another aspect illuminated by molecular markers is that, when
placing a new specimen into one of the 4 WHO grades, there still remains, considerable
variability between pathologists/centers. This is particularly so for Grades III and IV [17].
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9. Predictive and prognostic molecular markers: Clinical implications
Before embarking further on the discussion of molecular profiling of malignant gliomas, it is
imperative to make the distinction that, on the face of it, appears but a matter of simple
semantics. Within the context of this discussion, there exists a fundamental difference between
Prognostic and Predictive. Prognostic connotes the effect a certain marker gives an outcome
that is independent of the therapeutic intervention(s) employed. On the other hand, when a
marker is said to have predictive utility, this indicates that it foretells benefit specifically from
one type of treatment over others [17].
This discussion will first consider 1p/19q codeletion, a molecular profile that comes from
unbalanced translocation between chromosomes 1p and 19q, leading to net loss of genetic
material which ultimately leads to loss of one hybrid chromosome, and ultimately, loss of
heterozygosity [17]. Mutations have been found in genes that correspond to this translocation;
however, the biological underpinnings of these mutations have yet to be understood. The 1p/
19q Codeletion has been reliably found in oligodendroglial tumor subtypes that are inter‐
spersed between the WHO Grades [17]. Three randomized clinical trials (RTOG 9402, EORTC
26951, NOA-04) have shown that anaplastic oligodendroglioma patients with 1p/19q codele‐
tions have a survival benefit over those without the codeletion when receiving radiation
therapy (RT), alkylating chemotherapy, or both [18-20].
First, the RTOG 9402 trial randomly assigned 289 patients with anaplastic oligodendroglioma
or anaplastic oligoastrocytoma to receive either adjuvant RT alone or four cycles of Procarba‐
zine/CCNU/Vincristine (PCV) chemotherapy followed by RT (PCV-> RT). Of 201 patients
tested by FISH, 93 (46%) were found to have the codeletion. The first initial analysis of results
at 3 years out found a median progression free survival (PFS) of 1.7 years for the RT alone
contingent vs. 2.6 years for the PCV-> RT contingent; however, no overall survival benefit of
either study arm was found at this time, with a median overall survival (OS) of 4.9 years in the
PCV-> RT group vs. 4.7 years with RT alone. The 1p/19q codeletion was found to confer an
overall survival benefit, with a median OS of > 7 years vs. 2.8 years in those patients without
the codeletion. The type of treatment (RT vs. PCV-> RT) was not found to have statistically
significant bearing on this increase in OS in patients with tumors possessing the codeletion at
this interim analysis of study results. Extended follow up of patients in 2012 continued to show
an OS benefit of the 1p/19q codeletion but also found, interestingly, that PCV-> RT did improve
survival. At the 2012 reevaluation, those patients without the codeletion had median OS of 2.6
years for PCV-> RT vs. 2.7 years for RT alone, corresponding to earlier results. Those patients
with the codeletion who received PCV-> RT were found to have a median OS of 14.7 years vs.
7.3 years with RT alone, yielding a hazard ratio of 0.59 (95% CI, 0.37-0.95; P=0.03).
Very analogous to the RTOG trial was the EORTC 26951 trial, which randomized 368 patients
with anaplastic oligodendroglioma or anaplastic oligoastrocytoma to receiving either RT or
RT followed by six cycles of PCV (RT-> PCV). In this study, there were 78 patients (21%) whose
tumors were found to have the 1p/19q codeletion by FISH. When taken as a whole, the results
were similar to the RTOG study, finding that addition of PCV to RT increased PFS to 23 months
vs. 13.2 months but not finding a statistically significant difference in OS between the RT alone
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group (30.6 months) and the RT-> PCV group (40.3 months) at a median follow-up of 60
months. On stratification of patients based upon co-deletion status, a discernible survival
benefit was once again found, with no median OS reached for patients possessing the co-
deletion (irrespective of RT-> PCV vs. RT alone) vs. median OS of 25.2 and 21.4 months for RT-
> PCV and RT alone, respectively, in patients with partial or no deletion. Updated results from
2012, reflecting a median follow up of close to 12 years, went further to demonstrate that receipt
of adjuvant chemotherapy in patients possessing the co-deletion conferred an additional
survival benefit, the median OS for the subgroup of 42 patients with co-deleted tumors and
receiving RT-> PCV having not been reached vs. median OS for the subgroup of 38 patients
with co-deleted tumors receiving RT alone being 9.3 years. With respect to patients without
the co-deletion, this study's results were in accord with the RTOG trial, with a median OS of
25 months for the RT-> PCV subgroup vs. median OS of 21 months for the RT alone subgroup.
The third trial, NOA-04, by the German Neuro-Oncology Group, randomized 318 patients
with anaplastic astrocytoma, anaplastic oligodendroglioma, and mixed anaplastic oligoastro‐
cytoma into three single modality treatment groups--RT, PCV, or TMZ--by the ratio of 2:1:1,
respectively. This study had crossover design built into it, with patients experiencing unac‐
ceptable toxicity or progression from RT being further randomized to receive either PCV or
TMZ, or patients experiencing unacceptable toxicity or progression from chemotherapy
further randomized to RT. In this study, FISH analysis revealed 74 patients (23%) to possess
1p/19q co-deletion. The first analysis of results was undertaken at 54 months of follow-up at
which time 43% of patients had met the criteria for treatment failure, the primary endpoint of
the study. This analysis revealed that across all groups there was similar PFS and similar OS.
As with the RTOG and EORTC studies discussed above, the 1p/19q co-deletion was found to
bode well for prognosis, conferring a risk reduction of nearly 50% irrespective of treatment
arm.
Thusly, the molecular signature of 1p/19q codeletion has a predictive and prognostic utility as
it shows increased overall survival in patients who receive alkylating chemotherapy, radio‐
therapy or both as compared to those who do not possess it. However, this benefit was not
demonstratedin the group comprised of anaplastic astrocytoma which included 53% of the
patient population in this study. There was no statistical difference in outcome, time to
progression, nor overall survival whether patients were first treated with RT or alkylating
chemotherapy. However, given the worse overall prognosis in patients with anaplastic
astrocytoma the generally accepted approach to therapy is combined adjuvant chemotherapy-
radiation. This approach is extrapolated from data obtained in trials including patients with
glioblastoma.
MGMT is a DNA repair protein that canonically exemplifies the concept of chemotherapeutic
resistance. It does so by removing the alkylation of the O6 position of Guanine, which
represents the seminal mechanism of action of alkylating chemotherapeutic agents. The
beneficial epigenetic profile associated with MGMT is methylation of the MGMT promoter,
which silences the MGMT gene and thereby reduces the repair of chemotherapy induced
alkylation of DNA. This molecular marker was first suggested to have predictive utility by
Stupp et al in 2005 [21] in a post-hoc analysis of 203 (out of 573 patients treated in that study)
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assessable tumors. In that analysis, MGMT methylation status had significant bearing on
progression free survival (PFS) in patients from the experimental arm receiving TMZ in
addition to RT whereas it showed minimal benefit in PFS in those patients from the control
arm receiving RT alone. It was then shown to have prognostic, but not predictive, utility by
the results of the RTOG 0525 study, which showed an overall survival benefit of 23.2 months
in patients with MGMT methylated tumors vs. 16 months in patients with unmethylated
tumors irrespective of whether in the experimental arm (3 weeks on-one week off adjuvant
dose-intensified TMZ) or the control arm (standard TMZ) [22]. Based on these results, MGMT
methylation status is only accepted as a prognostic factor without predictive value in the
population studied. It is also very intriguing to note herein the results of studies aimed at
studying single vs. combined modality treatments in elderly patients greater than 70 years of
age in whom combined modality treatments are less tolerable and perhaps less effective. These
studies showed that in this subset of patients, MGMT methylation status has a predictive
utility. Patients with MGMT methylation had longer PFS when receiving chemotherapy plus
RT or chemotherapy alone as opposed to RT alone whereas patients without MGMT methyl‐
ation accrued no comparable survival benefit from chemotherapy [17]. This supposition--that
MGMT status is useful as a predictive tool in stratifying elderly patients to receipt of either
chemo or RT--was further corroborated by two trials--the NOA-08 trial and the Nordic Trial.
The NOA-08 trial, in brief, set out to prove non-inferiority of TMZ alone (one week on one
week off) with RT alone in patients 66 years of age and older. While there was no OS or PFS
difference between the two arms, it was noteworthy that patients with MGMT methylation
showed PFS of 8.4 months vs. PFS of 4.6 in the TMZ arm whereas in the RT arm, MGMT
methylation status had the opposite effect, conferring a PFS of 4.6 months in those without
MGMT methylation vs. 3.3 months in those with [23]. It is important to note that the temozo‐
lomide regimen used in this study varies significantly from the standard schedule used today
for patients with glioblastoma. In the Nordic Trial, patients were randomized into one of three
groups--standard RT (60 Gy) vs. hypofractionated RT (34 Gy over 2 weeks) vs. standard TMZ
schedule. Between the three groups, OS was found to be inferior in the standard RT group
when compared to TMZ and hypo fractionated RT. However, MGMT methylation did show
better OS in TMZ-treated patients whereas no such benefit was found in RT treated patients
[24]. In addition, a recently published meta-analysis performed by Yin et al [25], also supports
the predictive value of MGMT methylation status in the elderly population. These results make
it reasonable that MGMT status be brought to bear when considering single modality treatment
with RT or TMZ in elderly glioblastoma patients.
A third example of genetic/molecular markers that has proven prognostic is the genes IDH1
and IDH2 which encode the ubiquitous metabolic enzyme Isocitrate Dehydrogenase in the
cytoplasm and mitochondria, respectively. The native function of wild-type IDH protein is to
produce alpha-ketoglutarate. IDH Mutants catalyze a reaction that converts the native
metabolic intermediary alpha-ketoglutarate into D-2-hydroxyglutarate, an onco-metabolite
(this can be reliably measured by magnetic spectroscopy in situ and mediates the oncogenic
activity of the provoking IDH mutations [26]. The classification of gliomas based on IDH is to
categorize them based on IDH-wild-type vs. IDH-mutant gliomas. IDH-wild-type tumors are
inclusive of Grade I Pilocytic Astrocytomas and Primary Glioblastomas; these, of course,
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acquire their tumorigenesis independently of IDH-mutating pathways. IDH-mutant gliomas
are inclusive of most Grade II and Grade III Gliomas along with a few Secondary GBMs. It is
exceedingly interesting to note that IDH mutants tend to carry a better prognosis than IDH-
wild-type gliomas of the same histological grade (e.g. Secondary GBM carries a better
prognosis than Primary GBM). Indeed, an insightful pooled analysis of 382 WHO Grade III
and IV gliomas by Hartmann et al in 2010 corroborated this--that IDH status bears more
valuable prognostic information than simple histological grade [27]. So revelatory has the
delineation of gliomas been based on IDH status that, despite unequivocal similarities in
histological grade and morphology between tumors that would otherwise have classified them
together, it is now considered insufficient that they be grouped together if one were to be IDH-
wild-type and the other IDH mutant.
10. Angiogenesis: Vascular Endothelial Growth Factor (VEGF) and
Glioblastoma stem-like cells (GSC)
As alluded to earlier in the chapter, angiogenesis is an essential part of the pathogenesis of
malignant gliomas which, as a rule, are among the most vascularized of tumors [40, 41]. This
is due to: (1) upregulation of genes encoding proangiogenic factors, which include VEGF,
fibroblast growth factor (FGF), IL-8 and-6, hypoxia-inducible factor 1 alpha (HIF-1alpha) and
angiopoietins, and (2) downregulation of angiogenesis inhibitors, including thrombospodins,
angiostatin, endostatin and interferons. Indeed, the lynchpin that begets the transformation
from low grade to high grade gliomas is induction of expression of the above-cited proangio‐
genic factors [40]. The most prominent and well-characterized of the proangiogenic factors is
VEGF-A, commonly denoted simply as VEGF, which is directly secreted by tumor cells. VEGF
exerts its function by binding the receptor VEGFR2 on endothelial cells nearby the tumor. This
action initiates a paracrine signaling loop that results in the proliferation of endothelial cells
and, as a result, neo-vasculature. Interestingly, the level of VEGF produced by a tumor is
proportional to the degree of malignancy, the aggressiveness and poor outcome; high-grade
tumors are found to have orders of magnitude more VEGF than low grade tumors [13, 42].
There has thusly been a significant amount of clinical research focus on anti-angiogenic therapy
for malignant gliomas. Anti-angiogenic therapy has multiple hypothesized mechanisms of
action for the treatment of malignant gliomas. The primary mechanism of action is direct
cytotoxicity to endothelial cells, inducing apoptosis. This, by merit of the resultant attenuated
blood supply, decreases oxygen and nutrient delivery to tumor cells which preempts further
growth for a short period of time. A second hypothesized mechanism of action based upon
the results of select clinical studies is that, when used alongside cytotoxic chemotherapeutic
agents, anti-VEGF agents are thought to synergistically sensitize endothelial cells to penetra‐
tion by these cytotoxic agents. Intriguingly, it is also very likely that anti-VEGF agents work
to counteract an upsurge of VEGF expression and endothelial cell recruitment observed with
the tumoral insult caused by chemotherapy and radiation. Another hypothesis is that, during
a discrete window of time after administration, anti-VEGF agents elicit a phenomenon known
as “vascular normalization” during which there is reduced vessel diameter/permeability,
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improved vessel perfusion, a reduction in tumor interstitial pressure, and improved tumor
oxygenation. Summarily, these changes all translate into an observed improvement in the
delivery and efficacy of cytotoxic chemotherapy. A newer and exceedingly compelling
hypothesis is that antiangiogenic agents appear to exercise antagonism to Glioblastoma stem-
like cells (GSCs). GSCs play an inextricable part in the angiogenic potentiation of malignant
gliomas. They appear to contribute to the resistance that glioblastoma is known to have to
cytotoxic chemotherapy treatment by augmenting the repair of DNA damaged by cytotoxic
agents and activating the DNA damage checkpoint response system. Antiangiogenic therapy
appears to antagonize the functionality of GSCs by merit of GSCs embodying a categorically
structural and functional vascular niche in the tumoral micro-milieu. GSCs have been found
to upregulate VEGF expression, instigate formation of very angiogenic tumors in animal
models, and bear a predilection for stem cell hot beds in areas around endothelial cells. In the
self-same animal models, antiangiogenic agents appear to fundamentally disrupt the struc‐
tural framework of the hot beds in which GSCs reside and resultantly provoke GSC death.
The canonical agent that has garnered the most investigation and use is the humanized anti-
VEGF monoclonal antibody bevacizumab, originally used for treating colorectal cancer and
also used routinely for metastatic lung adenocarcinoma. Its use for CNS tumors, recurrent
gliomas in particular, was conceived of after improved outcomes were noted when it was used
in conjunction with chemotherapy for colorectal and lung cancers. Recurrent gliomas have
historically had a low radiographic response rate after re-exposure to temozolomide after
failing initial therapy, ranging from only 5-8%. However, in the very first published study of
the use of bevacizumab with irinotecan, a radiographic response rate of 66% (19 of 29 patients)
was found [40]. This was followed by a number of retrospective studies on recurrent gliomas
which showed progression free survival at 6 months (PF6) of 32-64% with bevacizumab vs.
21% PF6 rate for temozolomide [13]. The aggregate of these very positive results prompted
two phase 2 trials designed for the purposes of fast track FDA approval of bevacizumab for
the indication of recurrent gliomas. These two trials corroborated the prior results--a signifi‐
cant radiographic response rate and increase in PF6. The largest bevacizumab trial to date,
designated the BRAIN trial and conducted by Freidman et al in 2009, randomized patientswith
glioblastoma either after first or second recurrence to be treated with bevacizumab alone(n=85)
or bevacizumab plus irinotecan (n=82). Both response rates (using MacDonald response
criteria) and six month progression free survival were markedly higher when compared to
historical controls in both groups (higher response rate in bevacizumab plus irinotecan group).
However, overall survival was not statistically significant between the two groups at 9.2
months for bevacizumab alone and 8.7 months for the combination regimen. Bevacizumab
was well tolerated. The most common or significant adverse events included thromboembo‐
licevents, hypertension and proteinuria.
It is important to remind the reader here of the interdependence between angiogenesis and
the propagation of peritumoral edema in malignant gliomas. In fact, the original name for
VEGF was vascular permeability factor due to its increasing the permeability of tumor vessels,
which leads to the phenomenon of vasogenic brain edema. Vasogenic brain edema is a telltale
hallmark of malignant gliomas and qualifies much of the morbidity associated with them. It
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is for this reason that many patients with brain tumors are maintained over long periods of
time on high doses of corticosteroids, not without insubstantial side effects. Both clinical and
radiographic studies have found reductions in peritumoral edema with the administration of
anti-VEGF agents. This in turn allowed for reduction in corticosteroid use by as much as 50%,
a significant benefit for many of the patients experiencing the multifarious ill effects of chronic
corticosteroid use [41].
11. Hypoxia as means of resistance and poor outcome
Despite the many promising aspects of antiangiogenic therapy outlined above, there have
recently come to the fore many challenges that remain to the use of antiangiogenic agents for
the treatment of malignant gliomas. One challenge that has become evident is based upon, in
a matter of speaking, “tipping the balance” too far towards antiangiogenesis by significant use
of antiangiogenesis agents. Animal and human biopsy results have showed that when used
overzealously, antiangiogenic therapy actually works to promote a hypoxic environment
within the tumor bed. Tumor hypoxia has been well established as a formidable means of
resistance to chemotherapy and radiation [38]. Pre-clinical data obtained from xenograft
models suggests that hypoxia and the hypoxia-inducible factors (HIFs) play a central role in
maintaining the stem-like fraction in gliomas. This is achieved by providing the essential
cellular interactions and signals needed to arrest differentiation of these stem-like cells. These
interactions lead to stem-like cell survival and self-propagation. Upregulation of HIF-1alpha
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also activates autophagy, a lysosomal degradation pathway which may promote tumor cell
survival.
Though clinical trials have largely focused on VEGF-A antagonism through bevacuzimab,
there are a multitude of other pro-angiogenic factors/cytokines that contribute to glioma
angiogenesis, including basic FGF (bFGF), angiopoietins, PDGF, interleukin-8 (IL-8), and
hepatocyte growth factor/scatter factor (HGF/SF). It is thought that the contribution of these
alternative mediators of angiogenesis mediate the phenomenon of antioangiogenic therapy
resistance. In other words, these alternative proangiogenic factors are thought to allow for
continuing angiogenesis in the face of VEGFR inhibition. Quite sobering is the harsh reality
that though antiangiogenic therapy does prolong PFS and response rates are high in patients
with recurrent GBM/gliomas, progression of disease inevitably occurs and once tumor burden
breaks through, no therapeutic recourse presently exists. Confoundingly, patients with
recurrent GBM die very shortly after failing antiangiogenic therapy (figure 8) [44].
Figure 8. Post-Bevacizumab Salvage Therapy [44]
12. Response criteria and pseudoprogression
Anti-angiogenic agents also have made assessing response and progression a nebulous task.
Prior to the era of anti-angiogenic agents, response assessment was performed via the
MacDonald criteria which only utilized post-gadolinium MRI sequences. It was previously
accepted that a decrease in enhancement represents eradication of tumor but this has proven
not to be entirely valid with the use of anti-angiogenic agents. The development of a post-
treatment hypoxic microenvironment favors a metabolic change in the tumor cells toward
glycolysis, which leads to enhanced tumor cell invasion into the normal brain that is not
represented by MRI contrast enhancement. Pre-clinical data suggests that Anti-VEGF treat‐
ment reduces vessel contrast leakage, reduces vessel density and promotes invasiveness of
tumor cells which can be observed by an incongruent decrease in contrast enhancement along
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with hyper-intense T2 FLAIR MRI signal. Due to this new understanding, a revised response
criteria was developed that, in addition to post-gadolinium sequences, incorporates FLAIR
MRI sequences, steroid dependence and clinical stability. This new set of criteria is known as
the RANO criteria (Response Assessment in Neuro-Oncology) and now is standard in clinical
practice.
An important concept to invoke at this juncture, and one unique to the treatment of Glioblas‐
toma with chemotherapy and radiation, is that of Pseudoprogression. A few months after
completion of concurrent temozolomide with radiation, many patients show increased
contrast enhancement and T2/FLAIR hyperintensity in the radiation treatment field. This
generally occurs about 3 months after completion of chemo-radiation and sometimes persists
for about 6 months. The MacDonald criterion does not take this phenomenon into account
when defining disease progression. The more contemporary RANO criteria defines progres‐
sion at less than 12 weeks after chemoradiotherapy as the development of a new area of
enhancement outside of the prior radiation field, confirmed tumor via biopsy, or clinical
decline. Pseudoprogression, as the name implies, denotes these changes that are not due to
tumor progression, but rather due to unique cytotoxic effects on the tumor and its microen‐
vironment. Approximately ⅓ of patients with pseudoprogression are found to be symptomatic
due to associated inflammation and edema and require treatment with corticosteroids. There
is preliminary evidence at hand that indicates that administration of an anti-VEGF agent with
standard of care concurrent temozolomide and radiation may reduce the incidence of pseu‐
doprogression [45]. As in the case of vasogenic cerebral edema, this may spare, if not limit, the
ill effects of heavy corticosteroid use in many patients. Distinguishing pseudoprogression and
true disease progression is very challenging and new imaging techniques (i.e. MR spectrosco‐
py, MR perfusion study) are being developed to help with this dilemma and guide treatment
approach. Accumulating data shows promise using these new techniques but have yet to be
validated in large clinical studies.
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13. Bevacizumab as first line therapy
Two large phase III double-blinded randomized studies published in NEJM in February, 2014
evaluated the use of bevacizumab in the first line setting in patients with glioblastoma. Gilbert
et al, led a study that randomized 637 patients with newly diagnosed glioblastoma to standard
six weeks of chemo-radiotherapy (adjuvant temozolomide and concurrent radiotherapy)
followed by up to twelve months or until disease progression of maintenance temozolomide,
with or without bevacizumab starting at week four of chemo-radiotherapy [46]. The results
were disappointing in that no survival benefit was determined between the two groups. The
bevacizumab group reported a median overall survival (OS) of 15.7 months and the placebo
group had an OS of 16.1 months. Progression-free survival favored the bevacizumab group at
10.7 months vs. 7.3 months in the placebo group. Interestingly, over time the patients who
received bevacizumab did not benefit from a quality of life standpoint despite better response
rates. These points further reinforce the question as to whether PFS is an appropriate surrogate
maker for overall survival.
A second published in the same issue of NEJM performed by Chinot et al, studied the use
of bevacizumab in the front line setting as well [49]. Similar conclusions were reported in
this study compared to the performed by Gilbert et al. The treatment regimen used in the
study  differed  in  that  after  6  months  of  maintenance  temozolomide  with  or  without
bevacizumab were  continued with  bevacizumab alone or  placebo until  disease  progres‐
sion or until suffering from intolerable side effects. The results were again disappointing
in that the addition of bevacizumab to standard chemo-radiation and maintenance therapy
with this anti-angiogenic agent did not provide a survival benefit (72% and 33.9% one and
two year  survival  rate  respectively  in  the  bevacizumab group versus  66.3% and 30.1%)
despite  a  significantly better  PFS (10.6  months in bevacizumab group vs.  6.2  months in
placebo group). Baseline quality of life was maintained for a longer period of time in the
bevacizumab group.
These results, in particular the study by Gilbert et al, appears to possibly support the use of
maintenance temozolomide for twelve months instead of traditional standard therapy with
six months as conducted in the landmark study by Stupp et al now considered standard of
care. This is a question that every neuro-oncologist has to address when treating patients with
newly diagnosed glioblastoma. Although difficult to extrapolate data from two separate
studies, no large scale study has been performed making a direct comparison of twelve months
versus six months of maintenance temozolomide. However, this data suggests that twelve
months of maintenance temozolomide leads to an improvement in OS reporting 16.1 months
versus14.6 months reported in the EORTC trial led by Stupp et al.
14. Patterns of recurrence
As we gain more experience using anti-angiogenic agents in high grade gliomas, we also learn
more about what occurs after treatment failure. Mancuso et al. conducted a pre-clinical study
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using a mouse xengraft model to address the reversibility of VEGF inhibition after cessation
of anti-VEGF therapy. It was noted that even after a 50–60% reduction of tumour vascularity,
‘‘empty sleeves of basement membrane were left behind.’’ By day 7 after drug cessation,
tumours were fully re-vascularized, suggesting that these remaining empty sleeves of
basement membrane and pericytes are responsible for this tumor revascularization. These
basement membranes also serve as storage sites for angiogenic growth factors as well as
‘‘tracks’’ for tumor vascular regrowth. This “rebound” phenomenon has also been observed
in clinical studies (figure 9) [46]. This phenomenon appears to be associated with rapid clinical
demise and dismal prognosis.
Figure 9. Rebound progression after discontinuation of bevacizumab: Original tumor area seen on post-Gd T1
weighted (a) and FLAIR MRI (e) sequences prior to initiating therapy with bevacizumab in a patient with recurrent
high-grade glioma. Post-Gd T1 weighted (b) and FLAIR MRI (f) sequences that demonstrate partial response after 1
six-week cycle of treatment with bevacizumab. Post-Gd T1 weighted (c) and FLAIR MRI (g) sequences at the time of
bevacizumab failure and subsequent cessation of bevacizumab therapy. Post-Gd T1 weighted (d) and FLAIR MRI (h)
sequences at the time of “rebound” progression demonstrating a dramatic increase in area of enhancement and ab‐
normal FLAIR signal 6 weeks after cessation of therapy with bevacizumab. [44]
15. MicroRNA – Potential target
MicroRNAs (miRNAs) are molecules of RNA numbering 20-23 nucleotides that function to
interfere  with  messenger  RNA  (mRNA)  translation  into  protein,  the  final  step  in  gene
expression. Through a complex and elegantly-characterized molecular sequence of steps,
miRNAs function to “flag” mRNAs for decay, translational inhibition, or cleavage prior to
the process of translation. This, in turn, results in a decreased level of encoded proteins,
which  in  turn  affects  a  myriad  of  essential  cell  functions,  i.e.  growth,  proliferation,
metabolism, apoptosis, etc. [43] Interestingly, though miRNA constitutes roughly 1-3% of
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the human genome, it is postulated that these molecules have influence on as much as ~30%
of all  gene expression [44].  The expression of one mRNA may be affected by numerous
miRNAs; on the same token, one miRNA may affect the expression of multiple mRNAs
[44]. The deregulation of miRNA has been pivotally implicated in tumorigenesis; a positive
association has been found between those sites in the human genome associated with cancer
and areas of miRNA expression [44]. Furthermore, miRNAs have been found to exempli‐
fy both oncogenic and tumor suppressor functions in the tumorigenesis of pancreatic cancer,
prostate cancer,  thyroid cancer,  ovarian cancer,  colon cancer,  breast cancer,  and melano‐
ma. Of recent, the same has also been found in GBM wherein a multitude of miRNAs have
been reported to have roles in tumor suppression or oncogenesis.  Therapeutic strategies
with  respect  to  miRNA aim to  augment  tumor  suppression  or  antagonize  oncogenesis,
respectively. In the former case, it is postulated that viral vectors may be utilized to deliver
gene therapy to increase the in situ expression of tumor suppressive miRNAs. In the latter
case,  studies  pursuing  anti-miRNA therapies,  e.g.  the  use  of  anti-miRNA oligonucleoti‐
des, are underway for downregulation of oncogenic miRNAs [44].
16. Promising treatment approaches: Convection enhanced nanoparticle
delivery
An utterly novel modality of treatment actively under investigation is the utilization of
nanoparticles for the directed delivery of radionuclides into tumor bed. The premise behind
this modality is to maximize delivery of radiation therapy to tumor tissue while limiting
damage to surrounding normal tissue; external beam radiation is limited to 60 Gy due to
toxicity to normal tissue and lack of clinical benefit with higher dose of EBRT. Recently, studies
have been published in which radionuclide particles, e.g. 186-Rhenium, are encased in
liposomal nanoparticles and injected straight into the GBM tumor bed. In a study published
in 2012, Brenner et al injected 186-Rhenium liposomes directly into GBM Xenografts trans‐
planted into the brains of rat models. It was found that up to 1850 Gy could be delivered by
this method without overt clinical or microscopic evidence of toxicity. Those animals in the
experimental arm treated with 186-Rhenium liposomes were found to have a median survival
of 126 days vs. a median survival of 49 days for those animals in the control group. Compel‐
lingly, it was found that a large number of the animal subjects that were treated 21 days after
tumor grafting were found to have multiple objective indicators of tumor cure (See Figure
10). This included lack of detecting contrast-enhancing tumor on MRI, lack of detecting
luminescence by the luminescent molecule embedded in tumor cells, and no tumor cells found
on histopathology of resected animal brain tissue. These results suggest that nanoparticle
delivery of radioisotopes to the cavities of resected GBM either intra-or postoperatively may
have limitless therapeutic potential, particularly when used alongside adjuvant cytotoxic
chemotherapy [45].
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Figure 10. [45]
17. Conclusion
Glioblastoma is a deadly and devastating disease that is, as this chapter has made abundantly
clear, in need of the development of effective new agents to treat this aggressive tumor. Our
understanding of the intrinsic molecular and genetic make of this tumor, although still lacking,
has improved rapidly over the past decade and has shed light on current obstacles and is
leading to an array of promising agents on the horizon.
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